Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
1.
Int J Infect Dis ; 73: 93-101, 2018 Aug.
Article de Anglais | MEDLINE | ID: mdl-29879524

RÉSUMÉ

OBJECTIVE: To determine the course of serological tests in subjects with chronic Trypanosoma cruzi infection treated with anti-trypanosomal drugs. METHODS: A systematic review and meta-analysis was conducted using individual participant data. Survival analysis and the Cox proportional hazards regression model with random effects to adjust for covariates were applied. The protocol was registered in the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO; CRD42012002162). RESULTS: A total of 27 studies (1296 subjects) conducted in eight countries were included. The risk of bias was low for all domains in 17 studies (63.0%). Nine hundred and thirteen subjects were assessed (149 seroreversion events, 83.7% censored data) for enzyme-linked immunosorbent assay (ELISA), 670 subjects (134 events, 80.0% censored) for indirect immunofluorescence assay (IIF), and 548 subjects (99 events, 82.0% censored) for indirect hemagglutination assay (IHA). A higher probability of seroreversion was observed within a shorter time span in subjects aged 1-19 years compared to adults. The chance of seroreversion also varied according to the country where the infection might have been acquired. For instance, the pooled adjusted hazard ratio between children/adolescents and adults for the IIF test was 1.54 (95% confidence interval 0.64-3.71) for certain countries of South America (Argentina, Bolivia, Chile, and Paraguay) and 9.37 (95% confidence interval 3.44-25.50) for Brazil. CONCLUSIONS: The disappearance of anti-T. cruzi antibodies was demonstrated along the course of follow-up. An interaction between age at treatment and country setting was found.


Sujet(s)
Anticorps antiprotozoaires/sang , Maladie de Chagas/diagnostic , Adolescent , Adulte , Enfant , Enfant d'âge préscolaire , Maladie chronique , Test ELISA , Femelle , Technique d'immunofluorescence indirecte , Tests d'hémagglutination , Humains , Nourrisson , Mâle , Tests sérologiques , Jeune adulte
2.
Enferm. emerg ; 12(2): 110-114, abr.-jun. 2010. tab
Article de Espagnol | IBECS | ID: ibc-87703

RÉSUMÉ

Fundamento: La Enfermedad de Chagas afecta principalmente a poblaciones rurales tropicales y subtropicales de América. Su distribución se ha modificado por migraciones, emergiendo como un problema de salud urbano. El Departamento La Capital (Santa Fe, Argentina) es considerado de baja endemicidad para esta enfermedad. El objetivo del presente estudio fue caracterizar epidemiológicamente esta infección en una comunidad suburbana de La Capital. Métodos: Estudio descriptivo, de corte transversal. Lugar: Ángel Gallardo, Departamento La Capital, Santa Fe, Argentina. Periodo 2006-2007.Muestra: En mayores de 14 años: selección aleatoria de la muestra, n=72; en menores de 14años: totalidad de la población escolar previo consentimiento, n=116.Resultados: Seropositividad: 0,8% en <14 años, 29,2% en >14 años. Disminuyó con el nivel de instrucción. Resultaron infectados: 45,4% de los trabajadores rurales; 46,2% de los inmigrantes de Bolivia, Norte de Argentina y/o Norte de Santa Fe; 42,9% sabían que estaban infectados. Conclusiones: La prevalencia es muy superior a la estimada para la región. Aún en áreas sin riesgo entomológico, se debe buscar activamente la infección en comunidades con características epidemiológicas particulares. Muchos desconocen que están infectados y no se realizan los controles pertinentes. Se deben mantener los programas de control, para evitar el reinicio de ciclo vectorial en la región (AU)


Background: Chagas disease mainly affects tropical and subtropical rural populations of America. Its distribution has been modified by migrations, becoming a urban health problem.La Capital department in Santa Fe, Argentina, is considered a low endemicity area for this disease. The aim of the study was to characterize this infection in an epidemiological way in a suburban community of La Capital. Methods: Descriptive and cross- section study. Location: Ángel Gallardo, La Capital department, Santa Fe, Argentina. Period 2006-2007.Sample: Over 14 yo.: random selection, n=72; below 14 yo.: the whole school population with previous agreement, n=116.Results: Positive: 0,8% in <14 yo., 29,2% in >14 yo. Decrease with the school level. Infected:45,4% of rural workers; 46,2% of immigrants from Bolivia, North of Argentina and/or North of Santa Fe; 42,9% know they were infected. Conclusions: The prevalence is much superior to the one estimated for the region. Even in areas without entomological risk, the searching of the infection should be actively taken in communities with particular epidemiological characteristics. Many people do not know they are infected and they do not do the appropiate controls. The control programs should be kept in order to prevent the starting over of the vectorial cicle in the region (AU)


Sujet(s)
Humains , Maladie de Chagas/épidémiologie , Contrôle des maladies transmissibles/tendances , Maladies endémiques/statistiques et données numériques , Argentine/épidémiologie , Migration humaine/tendances
3.
Rev Soc Bras Med Trop ; 40(1): 1-10, 2007.
Article de Anglais | MEDLINE | ID: mdl-17486245

RÉSUMÉ

The efficacy of treatment with nifurtimox and/or benznidazole among adults with chronic Chagas disease with no previous electrocardiographic disturbances was evaluated over a mean follow-up of 21 years, by means of conventional serology, xenodiagnosis, clinical examination, electrocardiograms and chest X-ray. One hundred and eleven patients, between 17 and 46 years old, were studied: 54 underwent treatment (nifurtimox 27, benznidazole 27) and 57 remained untreated (control group). Xenodiagnosis was performed on 65% of them: 36/38 of the treated and 9/34 of the untreated patients had previous positive xenodiagnosis. Post-treatment, 133 xenodiagnoses were performed on 41 patients, all resulting negative. In the control group, 29 xenodiagnoses were performed on 14 patients; 2 resulted positive. Sera stored during the follow-up were simultaneously analyzed through conventional serology tests (IHA; DA-2ME; IIF). The serological evolution in the treated group was: a) 37% underwent negative seroconversion (nifurtimox 11, benznidazole 9); b) 27.8% decreased titers (nifurtimox 9, benznidazole 6), 9 showed inconclusive final serology (nifurtimox 7, benznidazole 2); c) 35.2% remained positive with constant titers (nifurtimox 7; benznidazole 12). The control group conserved the initial antibody levels during the follow-up. In the clinical evolution, 2/54 (3.7%) of the treated and 9/57 (15.8%) of the untreated patients showed electrocardiographic disturbances attributable to Chagas myocardiopathy, with a statistically relevant difference (p<0.05). Treatment caused deparasitation in at least 37% of the chronically infected adults and a protective effect on their clinical evolution.


Sujet(s)
Maladie de Chagas/traitement médicamenteux , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Adolescent , Adulte , Maladie de Chagas/sang , Maladie de Chagas/physiopathologie , Maladie chronique , Association de médicaments , Électrocardiographie , Méthodes épidémiologiques , Femelle , Humains , Mâle , Adulte d'âge moyen , Nifurtimox/effets indésirables , Nitroimidazoles/effets indésirables , Tests sérologiques , Facteurs temps , Résultat thérapeutique , Trypanocides/effets indésirables , Xénodiagnostic
4.
Rev. Soc. Bras. Med. Trop ; 40(1): 1-10, jan.-fev. 2007. tab, graf
Article de Anglais | LILACS | ID: lil-449161

RÉSUMÉ

The efficacy of treatment with nifurtimox and/or benznidazole among adults with chronic Chagas disease with no previous electrocardiographic disturbances was evaluated over a mean follow-up of 21 years, by means of conventional serology, xenodiagnosis, clinical examination, electrocardiograms and chest X-ray. One hundred and eleven patients, between 17 and 46 years old, were studied: 54 underwent treatment (nifurtimox 27, benznidazole 27) and 57 remained untreated (control group). Xenodiagnosis was performed on 65 percent of them: 36/38 of the treated and 9/34 of the untreated patients had previous positive xenodiagnosis. Post-treatment, 133 xenodiagnoses were performed on 41 patients, all resulting negative. In the control group, 29 xenodiagnoses were performed on 14 patients; 2 resulted positive. Sera stored during the follow-up were simultaneously analyzed through conventional serology tests (IHA; DA-2ME; IIF). The serological evolution in the treated group was: a) 37 percent underwent negative seroconversion (nifurtimox 11, benznidazole 9); b) 27.8 percent decreased titers (nifurtimox 9, benznidazole 6), 9 showed inconclusive final serology (nifurtimox 7, benznidazole 2); c) 35.2 percent remained positive with constant titers (nifurtimox 7; benznidazole 12). The control group conserved the initial antibody levels during the follow-up. In the clinical evolution, 2/54 (3.7 percent) of the treated and 9/57 (15.8 percent) of the untreated patients showed electrocardiographic disturbances attributable to Chagas myocardiopathy, with a statistically relevant difference (p<0.05). Treatment caused deparasitation in at least 37 percent of the chronically infected adults and a protective effect on their clinical evolution.


Avaliamos a eficácia do nifurtimox e/ou benznidazol, durante 21 anos em média, em adultos chagásicos crônicos sem alterações eletrocardiográficas iniciais, mediante sorologia convencional, xenodiagnóstico, exames clínicos, eletrocardiográficos e radiografia do tórax. Estudamos 111 pacientes (17 a 46 anos): 54 foram tratados (27 com nifurtimox e 27 com benznidazol) e 57 formaram o grupo controle. Foram submetidos ao xenodiagnóstico 65 por cento dos pacientes estudados: 36/38 tratados e 9/34 do grupo controle com xenodiagnóstico positivo prévio. Após tratamento, foram realizados 133 xenodiagnósticos em 41 pacientes, sendo todos negativos. Foram realizados 29 xenodiagnósticos em 14 pacientes do grupo controle, 2 foram positivos. A sorologia convencional foi realizada em soros estocados durante o seguimento. Evolução sorológica. Grupo tratado: a) 37 por cento negativaram (nifurtimox 11, benznidazol 9); b) 27,8 por cento diminuíram a titulação (nifurtimox 9, benznidazol 6), 9 deles apresentaram sorologia final discordante (nifurtimox 7, benznidazol 2; c) 35,2 por cento permaneceram positivos com titulação constante (nifurtimox 7, benznidazol 12). Grupo controle: conservou os níveis iniciais de anticorpos durante o seguimento. Evolução clínica: 2/54 (3,7 por cento) pacientes tratados e 9/57 não tratados apresentaram alterações eletrocardiográficas atribuíveis a miocardiopatia chagásica. Diferenças estatisticamente significantes (p<0,05). O tratamento produziu efeito de combate ao parasita em pelo menos 37 por cento dos infetados crônicos adultos e efeito protetor na evolução clínica.


Sujet(s)
Humains , Mâle , Femelle , Adolescent , Adulte , Adulte d'âge moyen , Maladie de Chagas/traitement médicamenteux , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Maladie chronique , Maladie de Chagas/sang , Maladie de Chagas/physiopathologie , Association de médicaments , Électrocardiographie , Méthodes épidémiologiques , Nifurtimox/effets indésirables , Nitroimidazoles/effets indésirables , Tests sérologiques , Facteurs temps , Résultat thérapeutique , Trypanocides/effets indésirables , Xénodiagnostic
5.
Rev. Soc. Bras. Med. Trop ; 37(5): 365-375, set.-out. 2004. ilus, tab, graf
Article de Portugais | LILACS | ID: lil-365845

RÉSUMÉ

Apresenta-se a avaliação clinicoepidemiológica de 95 crianças chagásicas crônicas em idades entre 1 e 14 anos moradoras de Santa Fé, Argentina, não tratadas e tratadas com nifurtimox ou benznidazol, com acompanhamento de até 24 anos. Todas tinham vários antecedentes de risco para transmissão do Trypanosoma cruzi: vetorial, congênito e/ou transfusão sangüínea. O diagnóstico da infecção foi feito através de sorologia convencional. O exame clínico foi complementado por eletrocardiograma, radiografias de tórax e, análise de sangue e urina para avaliação das funções hepáticas. No pós-tratamento, utilizaram-se técnicas idênticas às do diagnóstico, sendo que 33 crianças tiveram, também, avaliação parasitológica. Dentre 24 crianças não tratadas, 14 foram controlados por 8 a 24 anos e mantiveram sorologia positiva e o estado clínico inicial. Das 71 crianças tratadas, 49 tiveram acompanhamento de 4 a 24 anos: 14 mantiveram anticorpos anti-Trypanosoma cruzi; 6 resultados discordantes e 29 negativaram a sorologia. Destas, 9 apresentaram oscilações sorológicas, antes da negativação definitiva. A mediana do tempo de negativação pós-tratamento foi, respectivamente, de 3,5 e 8 anos para crianças de 1 a 6 e 7 a 14 anos. A percentagem de soronegativos diminuiu com a idade em que se medicou, desde 75 por cento em <4 anos até 43 por cento em > 9 anos. A intolerância ao tratamento foi de 3,8 por cento. Nenhuma criança modificou seu estado clínico nesta observação.


Sujet(s)
Humains , Mâle , Femelle , Nourrisson , Enfant d'âge préscolaire , Enfant , Adolescent , Maladie de Chagas/traitement médicamenteux , Maladies endémiques , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Argentine , Maladie chronique , Maladie de Chagas/diagnostic , Maladie de Chagas/transmission , Méthodes épidémiologiques , Résultat thérapeutique , Xénodiagnostic
6.
Rev Soc Bras Med Trop ; 37(5): 365-75, 2004.
Article de Portugais | MEDLINE | ID: mdl-15361952

RÉSUMÉ

Clinical and epidemiological results of 95 treated and untreated chronic chagasic children, with an up to 24 years follow-up period are presented. This population studied in the 1/14 age bracket, residing in Santa Fe city, Argentina, was diagnosed through Chagas-specific conventional serologic reactions. Clinical examination was supplemented with electrocardiogram, chest X-rays, and blood and urine tests for evaluating hepatic function. The drugs employed were nifurtimox or benznidazole. In post treatment period xenodiagnosis was made in 33 patients. Regarding Trypanosoma cruzi transmission, the studied individuals presented multi-risk antecedents: vectorial, congenital and/or blood transfusion. Among 24 untreated children 14 were controlled during 8/24 years: all this patients maintained the initial antibody concentration and clinical status. From 71 treated patients 49 were followed-up 4/24 years: 14 remained positive, 6 presented dubious results, and 29 showed final non-reactive results. 9 of this presented sometimes oscilating results. In 1/6 age bracket children, the serology turned negative after 3.5 years (median) once the treatment was finished, while patients treated in the 7/14 age bracket, the median of negativization was 8 years. 3.8% did not tolerate the drug. None of the groups changed their clinical condition. The untreated children did not change the serology. The percentage of treated children presenting negative serological results decrease according to the age when treatment was given: 75% became negative when treated at < or =4 years old and 43% when treated at > or =9 years old.


Sujet(s)
Maladie de Chagas/traitement médicamenteux , Maladies endémiques , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Adolescent , Argentine , Maladie de Chagas/diagnostic , Maladie de Chagas/transmission , Enfant , Enfant d'âge préscolaire , Maladie chronique , Méthodes épidémiologiques , Femelle , Humains , Nourrisson , Mâle , Résultat thérapeutique , Xénodiagnostic
7.
Acta bioquím. clín. latinoam ; 20(2): 139-44, jun. 1986. ilus, Tab
Article de Espagnol | BINACIS | ID: bin-31130

RÉSUMÉ

Para conocer la realidad epidemiológica de la enfermedad de Chagas de una determinada región se debe disponer de datos sobre diferentes aspectos de la misma y analizar sus resultados. El estudio de la infección al ingreso escolar es uno de los aspectos que importa al conjunto. En el presente trabajo se expone la metodología elaborada para el estudio de este grupo poblacional y los resultados de la experiencia piloto realizada (AU)


Sujet(s)
Enfant , Adulte , Humains , Mâle , Femelle , Étude comparative , Maladie de Chagas/épidémiologie , Enquêtes de Morbidité/méthodes , Tests sérologiques , Mères , Argentine
8.
Acta bioquím. clín. latinoam ; 20(2): 139-44, jun. 1986. ilus, tab
Article de Espagnol | LILACS | ID: lil-46784

RÉSUMÉ

Para conocer la realidad epidemiológica de la enfermedad de Chagas de una determinada región se debe disponer de datos sobre diferentes aspectos de la misma y analizar sus resultados. El estudio de la infección al ingreso escolar es uno de los aspectos que importa al conjunto. En el presente trabajo se expone la metodología elaborada para el estudio de este grupo poblacional y los resultados de la experiencia piloto realizada


Sujet(s)
Enfant , Adulte , Humains , Mâle , Femelle , Maladie de Chagas/épidémiologie , Enquêtes de Morbidité , Argentine , Mères , Tests sérologiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE